Seeking Alpha EN

Exagen GAAP EPS of -$0.20 misses by $0.01, revenue of $16.63M beats by $0.06M

Mar 10, 2026 &03031010202631; 12:03 UTC seekingalpha.com Trending 2/5

Read original on seekingalpha.com ↗

↘

Negative for markets

Sentiment score: -65/100

Moderate impact Short-term (days)

WHAT THIS MEANS

Exagen reported Q3 GAAP EPS of -$0.20, missing expectations by $0.01, while revenue of $16.63M slightly exceeded estimates by $0.06M. The company continues to operate at a loss despite modest revenue beat, indicating ongoing profitability challenges.

AI CONFIDENCE

75% High

SENTIMENT GAUGE

NEWS POWER SCORE

AFFECTED ASSETS

↓

XGN

XGNStock

Expected to decline

EPS miss of $0.01 and continued negative earnings despite revenue beat signals investor disappointment and ongoing path to profitability concerns

PRICE HISTORY

Loading chart...

⚡ SUGGESTED ACTION

Consider reducing exposure to XGN on this earnings miss. The revenue beat is overshadowed by the EPS miss and persistent losses, suggesting the company's path to profitability remains uncertain. Monitor upcoming guidance and cash burn rate closely.

KEY SIGNALS

EPS miss despite revenue beatNegative GAAP earnings continuationModest revenue growth insufficient to offset lossesProfitability timeline uncertainty

SECTORS INVOLVED

HealthcareDiagnosticsBiotechnology

Analysis generated on Mar 11, 2026 at 02:49 UTC

Disclaimer: This analysis is generated by artificial intelligence for informational purposes only and does not constitute financial advice, investment recommendation, or solicitation. Original reporting by Seeking Alpha. Always conduct your own research and consult a qualified financial advisor before making investment decisions.

Exagen GAAP EPS of -$0.20 misses by $0.01, revenue of $16.63M beats by $0.06M

RELATED INTELLIGENCE